NASDAQ · XERS
Xeris Biopharma Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for XERS: Nov 05, 2026
Xeris Biopharma Holdings, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.02. The reported EPS for the same quarter last year was $0.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.02 | $0.03 | $0.01 | 3 |
| Dec 2026 | $0.03 | $0.05 | $0.00 | 3 |
| Mar 2027 | $0.03 | $0.03 | $0.03 | 1 |
| Jun 2027 | $0.09 | $0.09 | $0.09 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · The Motley Fool · MarketBeat- RTTNews · Sep 30, 6:14 AM EDTBiotech Stocks At 52-Week Highs – IOVA +31%, XERS, GRAL, ABCL, SGHT(RTTNews) – The following biotech stocks reached a 52-week high on September 29, 2026, driven by key catalysts such as promising results from clinical trials or revised financial guidance.
- BNK Invest · Sep 28, 12:04 PM EDTMonday's ETF Movers: EBI, SLVRIn trading on Monday, the Longview Advantage ETF is outperforming other ETFs, up about 1.5% on the day. Components of that ETF showing particular strength include shares of Honeywell International, up about 7.5% and shares of Xeris Biopharma Holdings, up about 5.4% on the day.
- The Motley Fool · Aug 13, 12:15 PM EDTXeris (XERS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 7, 4:04 PM EDTXeris Biopharma Q2 Earnings Call HighlightsXeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 milli
- Zacks · Aug 6, 9:30 AM EDTCompared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key MetricsThe headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Aug 5, 8:35 PM EDTZevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass EstimatesZevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 8, 10:37 AM EDTXeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- MarketBeat · May 9, 4:07 AM EDTXeris Biopharma Q1 Earnings Call HighlightsXeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio. On the company’s earnings call, Chief Executi
- The Motley Fool · May 7, 4:13 PM EDTXeris (XERS) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 7, 9:30 AM EDTXeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- The Motley Fool · Mar 2, 11:32 AM ESTXeris Biopharma (XERS) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Mar 2, 10:56 AM ESTXeris Biopharma Delivers 44% FY25 Revenue Growth, Stock Up(RTTNews) – Xeris Biopharma Holdings, Inc. (XERS) reported record fourth-quarter and full-year 2025 results, underscoring strong momentum across its portfolio of therapies. The company also issued guidance for 2026, projecting continued revenue growth.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Xeris Biopharma Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.